Contribution: Industrial Research Assistance Program – Contributions to Firms
Paradox Immunotherapeutics Incorporated
$183,595.00
Development and candidate selection for amyloid-depleting antibodies for the treatment light chain and ALECT2 amyloidosis
FY 2022-23 · 2023-01-11
Summary
Identification, characterization, and screening of monoclonal antibodies for the treatment of ? and ?-light chain amyloidosis and drug discovery for ALECT2 amyloidosis. Potential candidates will be screened for in vitro binding affinity and specificity and for in vivo activity in cell and small animal models.
Department
Program
Industrial Research Assistance Program – Contributions to FirmsIndustrial Research Assistance Program-Contributions to Firms (linked with high confidence)
Location
Toronto|Toronto, Ontario, Canada
Recipient Type
For-profit organization
Business Number
758832877
Type
Contribution
Source
Proactive Disclosure - Grants and Contributions
Amendments
Each version of the agreement as published, oldest first, with its total as of that version. The amount above is the latest.
| Amendment | Date | Fiscal Year | Total |
|---|---|---|---|
| 0 | 2023-01-11 | 2022-23 | $195,500.00 |
| 2 | 2023-01-11 | 2022-23 | $183,595.00 |
As published
Additional Information
This agreement has been amended 2 time(s). The end date of this agreements has been modified by 152 days. The total amended value is -11,905 dollars.
Additional Information (French)
Cet accord a été modifié 2 fois La date de fin du présent accord a été changé de 152 jours. La valeur totale des modifications est de - 11 905 dollars.
Agreement End Date
2024-04-30
Agreement Number
1003392
Agreement Start Date
2023-01-11
Agreement Title
Development and candidate selection for amyloid-depleting antibodies for the treatment light chain and ALECT2 amyloidosis
Agreement Title (French)
Développement et sélection de candidats pour des anticorps de destruction de l’amyloïde pour le traitement de l’amyloïdose à chaîne légère et de l’amyloïdose ALECT2
Agreement Type
Contribution
Agreement Value
$183,595.00
Amendment Date
2023-11-28
Amendment Number
2
Coverage
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation. | Les projets des Contributions aux entreprises stimulent la création de richesse au Canada grâce à l’innovation technologique.
Description
Identification, characterization, and screening of monoclonal antibodies for the treatment of ? and ?-light chain amyloidosis and drug discovery for ALECT2 amyloidosis. Potential candidates will be screened for in vitro binding affinity and specificity and for in vivo activity in cell and small animal models.
Description (French)
Identification, caractérisation et criblage d’anticorps monoclonaux pour le traitement de l’amylose à chaînes légères et découverte de médicaments pour l’amylose ALECT2. Les candidats potentiels seront examinés pour l’affinité et la spécificité de la liaison in vitro et pour l’activité in vivo dans des modèles cellulaires et de petits animaux.
Expected Results
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Expected Results (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Federal Riding
University--Rosedale
Federal Riding (French)
University--Rosedale
Federal Riding Number
35110
NAICS Code
54171
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada
Program Name
Industrial Research Assistance Program – Contributions to Firms
Program Name (French)
Programme d’aide à la recherche industrielle – Contributions aux entreprises
Program Purpose
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Program Purpose (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Recipient Business Number
758832877
Recipient City
Toronto|Toronto
Recipient Country
CA
Recipient Legal Name
Paradox Immunotherapeutics Incorporated
Recipient Postal Code
M5G 0B7
Recipient Province or Territory
ON
Recipient Type
F
Reference Number
172-2022-2023-Q4-1003392
